Atezolizumab in patients with renal insufficiency and mixed variant histology: analyses from an expanded access program in platinum-treated locally advanced or metastatic urothelial carcinoma

Autor: Sumanta Pal, Joaquim Bellmunt, Jean Hoffman-Censits, Constanze Kaiser, Beiying Ding

Publikováno v: Journal for ImmunoTherapy of Cancer, Vol 8, Iss 2 (2020)

Background Atezolizumab is a treatment for locally advanced/metastatic urothelial carcinoma (mUC). However, its use in patients with renal insufficiency or UC with mixed variant histology (MVH) is not well characterized.Objective To report efficacy a

Externí odkaz: https://doaj.org/article/1d5e114dc6884499ae57a5fe02ce5812

Efficacy and Safety of Atezolizumab Plus Bevacizumab Following Disease Progression on Atezolizumab or Sunitinib Monotherapy in Patients with Metastatic Renal Cell Carcinoma in IMmotion150: A Randomized Phase 2 Clinical Trial

Autor: Cristina Suarez, Mario Sznol, Richard W. Joseph, Beiying Ding, Ning Leng, Alain Ravaud, John D. Hainsworth, Thomas E. Hutson, Brian I. Rini, David F. McDermott, Sergio Bracarda, Sumanta K. Pal, Allen Lee Cohn, Thomas Powles, Walter M. Stadler, James A. Reeves, Mahrukh Huseni, Christina Schiff, Lawrence Fong, Bernard Escudier, Kenji Hashimoto, Toni K. Choueiri, Michael B. Atkins, Robert J. Motzer

Publikováno v: European Urology. 79:665-673

Background The use of immune checkpoint inhibitors combined with vascular endothelial growth factor (VEGF)-targeted therapy as second-line treatment for metastatic clear cell renal cancer (mRCC) has not been evaluated prospectively. Objective To eval

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bbd4b5731294d1d03ff6daf0d1a9584b
https://doi.org/10.1016/j.eururo.2021.01.003

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Autor: Florian Huemer, Melissa Lynne Johnson, David S. Shames, György Losonczy, Aleksandra Szczesna, Aaron S. Mansfield, Alan Sandler, Maximilian Hochmair, Makoto Nishio, Juan Liu, Libor Havel, W. Lin, S. Lam, F. Kabbinavar, Leora Horn, Martin Reck, Stephen V. Liu, Ariel Lopez-Chavez, Beiying Ding, Maciej Krzakowski, Tony Mok

Publikováno v: New England Journal of Medicine. 379:2220-2229

Background Enhancing tumor-specific T-cell immunity by inhibiting programmed death ligand 1 (PD-L1)–programmed death 1 (PD-1) signaling has shown promise in the treatment of extensive-stag...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8dbff9bdd2be9f12ff3c401aa7c34629
https://doi.org/10.1056/nejmoa1809064

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Autor: Valeriy Breder, Beiying Ding, Andrew X. Zhu, Daneng Li, Ann-Lii Cheng, Richard S. Finn, Tae-You Kim, Ahmed Kaseb, Masafumi Ikeda, Philippe Merle, S. Mulla, Chen Huang, Juan Liu, Shukui Qin, Masatoshi Kudo, Peter R. Galle, Michel Ducreux, Wendy Verret, Derek Zhen Xu, Sairy Hernandez, Ho Yeong Lim

Publikováno v: The Lancet. Oncology. 22(7)

Summary Background Understanding patients' experience of cancer treatment is important. We aimed to evaluate patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma in th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3267d98f7949fd7d881cf93f82220fa
https://pubmed.ncbi.nlm.nih.gov/34051881

Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial::Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma

Autor: Motohide Uemura, Cristina Suarez, Howard Gurney, Elisabeth Piault-Louis, David F. McDermott, Elaine T. Lam, Caroleen Quach, Christina Schiff, Stéphane Oudard, Sergio Bracarda, Bernard Escudier, Qian Cindy Zhu, Carsten Grüllich, Robert J. Motzer, Beiying Ding, Frede Donskov, Michael B. Atkins, Brian I. Rini, Susheela Carroll, Walter M. Stadler, Thomas Powles

Publikováno v: Atkins, M B, Rini, B I, Motzer, R J, Powles, T, McDermott, D F, Suarez, C, Bracarda, S, Stadler, W M, Donskov, F, Gurney, H, Oudard, S, Uemura, M, Lam, E T, Grüllich, C, Quach, C, Carroll, S, Ding, B, Zhu, Q C, Piault-Louis, E, Schiff, C & Escudier, B 2020, ' Patient-Reported Outcomes from the Phase III Randomized IMmotion151 Trial: Atezolizumab + Bevacizumab versus Sunitinib in Treatment-Naïve Metastatic Renal Cell Carcinoma ', Clinical Cancer Research, vol. 26, no. 11, pp. 2506-2514 . https://doi.org/10.1158/1078-0432.CCR-19-2838

Purpose: Patient-reported outcomes (PRO) were evaluated in the phase III IMmotion151 trial (NCT02420821) to inform overall treatment/disease burden of atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic ren

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08f97b77f41738e00c8827f89a7e2cea
https://pure.au.dk/portal/da/publications/patientreported-outcomes-from-the-phase-iii-randomized-immotion151-trial(0e8fcf48-68ed-46f8-903a-fd0d93d00297).html